Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

Publisher： Spandidos Publications

E-ISSN： 1791-2431|33|1|391-396

ISSN： 1021-335X

Source： Oncology Reports, Vol.33, Iss.1, 2015-01, pp. : 391-396

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

By Ayoola Ayodele   Barochia Amit   Belani Kiran   Belani Chandra P.  

Cancer Investigation, Vol. 30, Iss. 5, 2012-05 ,pp. : 433-446

Informa Healthcare

Access to resources Recommend Favorite

Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

By        

Molecular Medicine Reports, Vol. 10, Iss. 2, 2014-01 ,pp. : 931-938

Spandidos Publications

Access to resources Recommend Favorite

EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?

By Califano Raffaele  

Targeted Oncology, Vol. 3, Iss. 3, 2008-07 ,pp. : 173-186

Springer Publishing Company

Access to resources Recommend Favorite

Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

By Pilotto Sara   Bria Emilio  

Lung Cancer Management, Vol. 2, Iss. 2, 2013-04 ,pp. : 89-92

Future Medicine

Access to resources Recommend Favorite

The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors

By Belani Chandra P.  

Cancer Investigation, Vol. 28, Iss. 4, 2010-04 ,pp. : 413-423

Informa Healthcare

Access to resources Recommend Favorite